Increased concentrations of growth factors and activation of the EGFR system in breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 10, 2012, Pages 1809-1818

  Olsen, Dorte Aa ^a   Bechmann, Troels ^a,b   Østergaard, Birthe ^a   Wamberg, Peter A ^a   Jakobsen, Erik H ^a   Brandslund, Ivan ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Breast cancer; Epidermal growth factor receptor 1 (EGFR); HB EGF; HER2; Ligands; Luminex; Prognosis

Indexed keywords

AMPHIREGULIN; BETACELLULIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIREGULIN; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DEVICE; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84867758772     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0823     Document Type: Article

References (27)

1. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
2. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Sorensen PD, Jakobsen EH, Langkjer ST, Bokmand S, Ostergaard B, Olsen DA, et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 2009;47:1117-23.
5. Olsen DA, Ostergaard B, Bokmand S, Wamberg PA, Jakobsen EH, Jakobsen A, et al. HER1-4 protein concentrations in normal breast tissue from breast cancer patients are expressed by the same profile as in the malignant tissue. Clin Chem Lab Med 2009;47:977-84.
6. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42.
7. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
10. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
11. Dittadi R, Donisi PM, Brazzale A, Cappellozza L, Bruscagnin G, Gion M. Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue. Br J Cancer 1993;67:7-9.
12. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, et al. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 1996;56:3823-30.
13. Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006;11:3-11.
14. Olsen DA, Ostergaard B, Bokmand S, Wamberg PA, Jakobsen EH, Brandslund I. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med 2007;45:177-82.
15. Yotsumoto F, Oki E, Tokunaga E, Maehara Y, Kuroki M, Miyamoto S. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int J Cancer 2010;127:2707-17.
16. Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, et al. Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 1994;69:903-10.
17. Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645-56.
18. Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 2006;42:636-45.
19. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009;11:R11.
20. Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 2008;10:R49.
21. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 2007;25:4405-13.
22. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008;19:73-80.
23. Ito Y, Takeda T, Higashiyama S, Noguchi S, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001;67:81-5.
24. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005;11:4783-92.
25. Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H, et al. A novel anti-human HB-EGF monoclonal antibody with multiple anti-tumor mechanisms against ovarian cancer cells. Clin Cancer Res 2011;17:6733-41.
26. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C, Pironi F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 2004;53:1041-8.
27. Tsujioka H, Yotsumoto F, Hikita S, Ueda T, Kuroki M, Miyamoto S. Targeting the heparin-binding epidermal growth factorlike growth factor in ovarian cancer therapy. Curr Opin Obstet Gynecol 2011;23:24-30.